Myriad Genetics (MYGN) 2025 Outlook: Investing Framework
Dive into how to read myriad genetics (mygn) 2025 earnings transcripts, spot growth drivers, assess risk, and build a...
Biotech
Biotech insights await. This page curates 5 articles on Tempus, Moderna, Praxis, ImmunityBio and market moves to help you evaluate stocks and sharpen your portfolio strategy.
58 articles
Madrigal (MDGL) 2025 Earnings: What Investors Should Know
As Madrigal prepares to report its 2025 earnings, investors weigh pipeline progress, cash runway, and milestones ahea...
Biotech Investor Adds Million as Krystal Biotech Revenue Rises
A major biotech investor is stepping up its bet on Krystal Biotech as the company posts robust 2025 revenue. This mov...
Using Saliva Detect Disease Faces Billing and Access Hurdles
Saliva-based tests promise easy disease detection, but coverage gaps and costs could slow adoption. Here’s how it cou...
Orbimed Advisors Trims $125 After Breakout Year in Biotech
A major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
Praxis Medicines 2025 Earnings: Key Investor Insights
As earnings season arrives, praxis medicines 2025 earnings offer a compelling snapshot of where the company stands. T...
Stock Market Today, Feb: ImmunityBio Up on Anktiva EU OK
ImmunityBio sails higher after the EU green lights ANKTIVA for bladder cancer, igniting waves across biotech stocks. ...
Moderna Stock Just Popped: What Investors Need to Know
A regulatory hint sent Moderna stock just popped, but the journey from acceptance to approval matters. This guide bre...
ImmunityBio Stock Soaring Today: Key Catalysts Unpacked
ImmunityBio has grabbed headlines as shares surge amid regulatory wins and pipeline potential. This deep dive explain...
Tempus Stock Today What Sparks Rally Ahead of Earnings
Tempus AI shares rose as it introduced an AI-powered HRD-RNA cancer diagnostic algorithm, signaling momentum before i...